Tenax Therapeutics Inc (TENX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $73.77M
Last updated: Nov 17, 2026 at 11:05 AM ET
Tenax Therapeutics Inc (TENX) Stock Forecast
Analysts expect Tenax Therapeutics (TENX) to earn -$1.39 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 6 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.30, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 60% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 5 | 50.0% |
| Hold | 4 | 40.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.39
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.31
- EPS consensus
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.39 | -$1.70 to -$1.08 | 9 |
| Dec 31, 2027 | -$1.31 | -$1.64 to -$0.60 | 8 |
Quarterly Estimates
The EPS consensus is -$0.36 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.36 | -$0.42 to -$0.21 | 10 |
| Mar 31, 2027 | -$0.36 | -$0.42 to -$0.33 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 2 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.45.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.39 | -$1.45 | -$1.45 | -$1.45 | -$1.45 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.31 | -$1.50 | -$1.50 | -$1.50 | -$1.46 | N/A |
| Quarter ending Mar 31, 2027 | -$0.36 | -$0.39 | -$0.39 | -$0.39 | -$0.38 | N/A |
Frequently Asked Questions About TENX
What is the TENX stock forecast?
Consensus analyst estimates put Tenax Therapeutics's EPS at -$1.39 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate TENX stock?
Of 10 analysts covering Tenax Therapeutics, 1 rates it Strong Buy, 5 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TENX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.39, with estimates from -$1.70 to -$1.08 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.31, with estimates from -$1.64 to -$0.60 from 8 analysts.
How many analysts cover TENX?
10 analysts rate Tenax Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TENX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors